¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"REC"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • rectal shelf
    Á÷Àå¼±¹Ý, °ðâÀÚ¼±¹Ý
  • rectal sinus
    Á÷Àå±¼, °ðâÀÚ±¼, Á÷À嵿
  • rectal suppository
    Á÷ÀåÁ¾à
  • rectal swab
    Á÷Àå¸éºÀ¹ý, °ðâÀÚ¸éºÀäÃë¹ý
  • rectal tube
    Á÷Àå°ü, °ðâÀÚ°ü
  • rectal urgency
    ´ëº¯¸øÂüÀ½, ´ëº¯Àý¹Ú
  • rectal valve
    Á÷ÀåÆÇ¸·, °ðâÀÚÆÇ¸·
  • rectal venous plexus
    Á÷ÀåÁ¤¸Æ¾ó±â, °ðâÀÚÁ¤¸Æ¾ó±â
  • rectalgia
    Á÷ÀåÅë(Áõ), °ðâÀÚÅëÁõ
  • rectangular coordinate
    Á÷°¢ÁÂÇ¥
  • rectectomy
    Á÷ÀåÀýÁ¦(¼ú), °ðâÀÚÀýÁ¦(¼ú)
  • rectification
    1. ±³Á¤ 2. Á¤·ù 3. Á¤¼ö
  • rectifier
    Á¤·ù±â
  • rectifier tube
    Á¤·ù°ü
  • rectilinear
    Á÷¼±-
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • rectal
    °ðâÀÚ-, Á÷Àå-
  • rectal aganglionosis
    °ðâÀڽŰæÀý¾øÀ½Áõ
  • rectal ampulla
    °ðâÀÚÆØ´ë, Á÷À寨´ë
  • rectal anesthesia
    °ðâÀÚ¸¶Ãë, Á÷À帶Ãë
  • rectal application
    °ðâÀÚ³»Àû¿ë, Á÷Àå³»Àû¿ë
  • rectal artery
    °ðâÀÚµ¿¸Æ
  • rectal atresia
    °ðâÀÚÆó¼âÁõ, Á÷ÀåÆó¼âÁõ
  • rectal bleeding
    °ðâÀÚÃâÇ÷, Á÷ÀåÃâÇ÷
  • rectal crisis
    °ðâÀÚ¹ßÀÛ, Á÷Àå±ÞÅëÁõ
  • rectal dyschezia
    °ðâÀڹ躯°ï¶õ, Á÷Àå¹èº¯°ï¶õ
  • rectal fistula
    °ðâÀÚ»û±æ, Á÷Àå·ç
  • rectal hernia
    Á÷ÀåÇ츣´Ï¾Æ, °ðâÀÚÇ츣´Ï¾Æ
  • rectal incontinence
    (¢¡fecal incontinence) ´ëº¯Âñ²ûÁõ, ´ëº¯½Ç±Ý
  • rectal infusion
    °ðâÀÚÁÖÀÔ, Á÷ÀåÁÖÀÔ
  • rectal instillation
    °ðâÀÚ¹æ¿ïÁÖÀÔ, Á÷ÀåÁ¡ÀûÁÖÀÔ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • reciprocating supraventricular tachycardia
    Àç±Í¼º ½É½Ç»ó¼º ºó¸Æ.
  • reciprocity law
    »ó¹Ý¹ýÄ¢(ßÓÚãÛööÎ).
  • recirculating system
    Àç¼øÈ¯(¹æ)½Ä .
  • recirculation
    Àç¼øÈ¯
  • recirculation time
    Àç¼øÈ¯½Ã°£(î¢âàü»ãÁÊà).
  • reckoning test
    °¡»ê½ÃÇè(ʥߩãËúÐ).
  • reclaimed
    Àç»ý(î¢ßæ)µÈ.
  • reclaimed gypsum
    Àç»ý ¼®°í(î¢ßæà´ÍÇ).
  • reclaimed rubber
    Àç»ý°í¹«.
  • reclaiming process
    Àç»ý¹ý(ËøË×ËÑ).
  • reclotting phenomenon
    ÀçÀÀ°íÇö»ó(î¢ëêͳúÞßÚ).
  • recognition
    ÀνÄ(ìããÛ).
  • recognition
    ÀÎÁö
  • recognition, self
    ÀÚ±âÀÎÁö
  • recoil atom
    ¹Ýµµ¿øÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • recessus palatinum ³ª
    ±¸°³¿À¸ñ, ±¸°³ÇÔ¿ä(Ï¢ËÏùèèê).
  • recessus paracolici ³ª
    °áÀå¿·¿À¸ñ, °áÀ广ÇÔ¿ä(Ì¿ Û¨ùèèê).
  • recessus paraduodenalis ³ª
    ½ÊÀÌÁöÀå¿·¿À¸ñ, ½ÊÀÌÁöÀ广ÇÔ¿ä(ä¨ì£ò¦ Û¨ùèèê ).
  • recessus pharyngeus ³ª
    ÀεοÀ¸ñ, ÀεÎÇÔ¿ä(ìÖÔéùèèê).
  • recessus phrenicohepatici ³ª
    Ⱦ°Ý¸·°£¿À¸ñ, Ⱦ°Ý°£ÇÔ¿ä(üô̰Êàùèèê).
  • recessus pinealis ³ª
    ¼Û°úü¿À¸ñ, ¼Û°úÇÔ¿ä(áæÍýùèèê).
  • recessus piriformis ³ª
    Á¶·Õ¹Ú¿À¸ñ, ÀÌ»óÇÔ¿ä(ì±ßÒùèèê).
  • recessus pleurales ³ª
    È丷¿À¸ñ, È丷µ¿(ýØØ¯÷Ó).
  • recessus posterior ³ª
    ÈÄ¿À¸ñ, ÈÄÇÔ¿ä (ý­ùèèê).
  • recessus praecardiacus ³ª
    ¾Õ½ÉÀå¿À¸ñ, ½ÉÀüÇÔ¿ä(ãýîñùèèê).
  • recessus retrocecalis ³ª
    ¸ÍÀåµÚ¿À¸ñ, ¸ÍÀåÈÄÇÔ¿ä(Øî ý­ùèèê).
  • recessus retroduodenalis ³ª
    ½ÊÀÌÁöÀåµÚ¿À¸ñ, ½ÊÀÌÁöÀåÈÄÇÔ¿ä(ä¨ì£ò¦ ý­ùè èê).
  • recessus rostralis ³ª
    ÀÔÂÊ¿À¸ñ, ÀüÇÔ¿ä(îñùèèê).
  • recessus sacciformis articulationis cubiti ³ª
    ÁÖ°üÀý³¶»óÇÔ¿ä( μï½Ò¥ßÒùèèê).
  • recessus sacciformis ³ª
    ÁָӴϸð¾ç¿À¸ñ, ³¶»óÇÔ¿ä(Ò¥ßÒùèèê).
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
receptors, IgE Specific molecular sites on the surface of b- and T-lymphocytes which combine with iges. Two subclasses exist: low affinity receptors (fc epsilon ri) and high affinity receptors (fc epsilon rii).
(12 Dec 1998)
receptors, IgG Specific molecular sites on the surface of various cells, including B-lymphocytes and macrophages, that combine with iggs. Three subclasses exist: fc gamma ri (the CD64 antigen, a low affinity receptor), fc gamma rii (the CD32 antigen, a high affinity receptor), and fc gamma riii (the CD16 antigen, a low affinity receptor).
(12 Dec 1998)
receptors, immunologic Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behaviour of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere.
(12 Dec 1998)
receptors, insulin Cell surface proteins that bind insulin and trigger intracellular changes which influence the behaviour of cells. The best understood physiological consequence of insulin receptor activation is increased transport of glucose into most cells, which controls the rate of carbohydrate metabolism. The insulin receptor is a multifunctional protein complex that has intrinsic tyrosine kinase activity and is capable of autophosphorylation.
(12 Dec 1998)
receptors, insulin-like-growth factor I Specific proteins on or in cells to which insulin-like growth factor I (somatomedin c) binds and thereby modifies the function of the cells. These receptors contain transmembrane and cytosolic domains, bind igf-I preferentially, and have high-affinity sites for igf-II. The alpha-subunit has a mw of 130 kD and the beta subunit possesses tyrosine kinase activity.
(12 Dec 1998)
receptors, insulin-like-growth-factor II Specific proteins on or in cells to which insulin-like growth factor II and mannose-6-phosphate bind and thereby modify the function of the cells. These receptors have a mw of 250 kD and possess no tyrosine kinase activity.
(12 Dec 1998)
receptors, interferon Specific molecular sites or structures on or in cells with which interferons react or to which they bind in order to modify the function of the cells. Interferons exert their pleiotropic effects through two different receptors. Alpha- and beta-interferon crossreact with common receptors, while gamma-interferon initiates its biological effects through its own specific receptor system.
(12 Dec 1998)
receptors, interleukin Cell surface proteins that bind interleukins and trigger intracellular changes influencing the behaviour of cells.
(12 Dec 1998)
receptors, interleukin-1 Specific molecular sites or structures on cells with which interleukin-1 reacts or to which it binds to modify the function of the cells. The il-1 receptor on T-lymphocytes and fibroblasts is composed of a single polypeptide chain that binds both il-1 alpha and il-1 beta. The molecular weight of this high-affinity receptor is believed to be 80 kD.
(12 Dec 1998)
receptors, interleukin-2 Receptors present on activated t- and B-cells as a complex consisting of a 55 kD peptide, which reacts with the anti-tac monoclonal antibody, and a 75 kD non-tac interleukin-2-binding peptide. The receptor is present in two forms, one with a very high affinity and the other with low affinity for il-2. The high-affinity form appears to mediate exclusively the growth-promoting response to il-2. The receptor is present in large numbers on resting HTLV-I leukaemia cells, but not on normal resting cells.
(12 Dec 1998)
receptors, interleukin-3 Phosphotyrosine-containing proteins, mw 140 kD. They form a stable complex with interleukin-3 with an apparent mass of 170 kD. They are found on a variety of cells and activate interleukin-3.
(12 Dec 1998)
receptors, interleukin-4 Receptors present on a wide variety of haematopoietic and non-haematopoietic cell types and various human tumours. Two forms of the receptor have been described, soluble and membrane-bound. Low affinity and high affinity receptors for il-4 have been reported.
(12 Dec 1998)
receptors, interleukin-6 <chemical> Receptors present on t cells, mitogen-activated B-cells, peripheral monocytes, and some macrophage- and B-cell-derived tumour cell types. The receptor is a strongly glycosylated protein of 80 kD and a length of 468 amino acids.
Pharmacological action: growth inhibitors.
(12 Dec 1998)
receptors, invertebrate peptide Cell surface receptors for invertebrate peptide hormones or neuropeptides.
(12 Dec 1998)
receptors, kainic acid Cell surface proteins that bind glutamate and directly gate ion channels. Kainic acid receptors were originally discriminated from other glutamate receptors by their affinity for the agonist kainic acid. Activation of kainic acid receptors is generally excitatory to cells. Subtypes have been cloned, and for some the traditional distinction from ampa receptors may not apply.
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 5 ÆäÀÌÁö: 9
  • Receptor, Fibroblast Growth Factor, Type 3 - »õâ A fibroblast growth factor receptor that regulates CHONDROCYTE growth and CELL DIFFERENTIATION. Mutations in the gene for fibroblast growth factor receptor 3 have been associated with ACHONDROPLASIA; THANATOPHORIC DYSPLASIA and NEOPLASTIC CELL TRANSFORMATION.
    Synonyms : FGFR3 Protein, Fibroblast Growth Factor Receptors 3, Receptor 3, Fibroblast Growth Factor
  • Receptor, Fibroblast Growth Factor, Type 4 - »õâ A fibroblast growth factor receptor that is mainly expressed in LUNG; KIDNEY; PANCREAS; and SPLEEN. It also plays an important role in SKELETAL MUSCLE development and can contribute to NEOPLASTIC CELL TRANSFORMATION.
    Synonyms : Fibroblast Growth Factor Receptors 4, Receptor 4, Fibroblast Growth Factor
  • Receptor, Fibroblast Growth Factor, Type 5 - »õâ The most divergent of the known fibroblast growth factor receptors. It does not contain an intracellular TYROSINE KINASE domain and has been shown to interact with FIBROBLAST GROWTH FACTOR 2. Fibroblast growth factor receptor 5 is found primarily in skeletal tissue.
    Synonyms : FGF Receptor-Like Protein, Fibroblast Growth Factor Receptor-5, Receptor 5, Fibroblast Growth Factor, Receptor, Type 5 Fibroblast Growth Factor, FGF Receptor Like Protein, Receptor-Like Protein, FGF
  • Receptor, Galanin, Type 1 - »õâ The most abundant galanin receptor subtype. It displays a high affinity for the full-length form of GALANIN.
    Synonyms : GALR1 Galanin Receptor, Galanin-1 Receptor, Galanin 1 Receptor, Galanin Receptor, GALR1, Receptor 1, Galanin, Receptor, GALR1 Galanin, Receptor, Galanin-1
  • Receptor, Galanin, Type 2 - »õâ A galanin receptor subtype with broad specificity for full length GALANIN, galanin peptide fragments and GALANIN-LIKE PEPTIDE.
    Synonyms : GALR2 Galanin Receptor, Galanin-2 Receptor, Galanin 2 Receptor, Galanin Receptor, GALR2, Receptor 2, Galanin, Receptor, GALR2 Galanin, Receptor, Galanin-2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 5 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
receiver A receiver is a tuner combined with an amplifier and/or loudspeaker. It is commonly used in home theater settings, although it is believed that standalone tuners have superior audio quality. These devices feature multiple inputs, allowing connections from record players, CD players, tape decks, and video devices such as VCRs, DVD players, and televisions. Digital audio S/P-DIF connections are also common today. ...
Ãâó: en.wikipedia.org/wiki/Receiver_(home_stereo)
recessive In genetics, the term "recessive gene" refers to an allele that causes a phenotype (visible or detectable characteristic) that is only seen in a homozygous genotype (an organism that has two copies of the same allele). Every person has two copies of every gene, one from mother and one from father. If a genetic trait is recessive, a person only needs to inherit two copies of the gene for the trait to be expressed. ...
Ãâó: en.wikipedia.org/wiki/Recessive
reciprocal innervation René Descartes (1596-1650) was one of the first to conceive a model of reciprocal innervation (in 1626) as the principle that provides for the control of agonist and antagonist muscles. The concept of reciprocal innervation is associated with the notion of paired muscular activity. Skeletal muscles exist in antagonistic pairs, which work “against” one another. In order to reach optimum efficiency, one is inhibited while the other is excited. ...
Ãâó: en.wikipedia.org/wiki/Reciprocal_innervation
recessive trait In genetics, the term "recessive gene" refers to an allele that causes a phenotype (visible or detectable characteristic) that is only seen in a homozygous genotype (an organism that has two copies of the same allele). Every person has two copies of every gene, one from mother and one from father. If a genetic trait is recessive, a person only needs to inherit two copies of the gene for the trait to be expressed. ...
Ãâó: en.wikipedia.org/wiki/Recessive_trait
recta Ground Clematis
Ãâó: en.wikipedia.org/wiki/Clematis
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • rechristen
    ´Ù½Ã ¸í¸íÇÏ´Ù;´Ù½Ã À̸§À» ºÙÀÌ´Ù(rebaptize)
  • recidivism
    »ó½ÀÀû ¹üÁË
  • recidivism
    »ó½ÀÀû ¹üÇà;»ó½À(¼º);Àç¹ü(¼º)
  • recidivist
    Àç¹üÀÚ;»ó½À¹ü !
  • recidivous
    Á˸¦ °ÅµìÇϱ⠽¬¿î;»ó½À¹üÀûÀÎ
  • recip.
    reciprocal;reciprocity
  • recipe
    ó¹æ
  • recipe
    (¿ä¸®ÀÇ)Á¶¸®¹ý;¿ä¸®¹ý;ó¹æ(Àü);¹æ¹ý;ºñ°á;ºñ¹æ;ºñÃ¥
  • recipience,-ency
    ¼ö·É;¼ö³³;¼ö¿ë;°¨¼ö¼º;¼ö¿ë¼º
  • recipient
    ¼öÃëÀÎ
  • recipient
    ¼ö³³ÀÚ;¼ö·ÉÀÎ;¿ë±â;¼ö·ÉÇÏ´Â;(Àß)¹Þ¾ÆµéÀÌ´Â;°¨¼ö¼ºÀÌ ÀÖ´Â
  • reciprocal
    ¼­·Î°£ÀÇ; »óÈ£ÀÇ
  • reciprocal
    »óÈ£°£ÀÇ(mutual);È£ÇýÀûÀÎ;»ó¹ÝÇÏ´Â;»ó¹ÝÀÇ;¿ªÀÇ;È¥¿ëÇÒ ¼ö ÀÖ´Â;¿ª¼ö;¹Ý¼ö;~ly ¼­·Î;È£ÇýÀûÀ¸·Î;»ó¹ÝµÇ°Ô
  • reciprocal pronoun
    »óÈ£ ´ë¸í»ç
  • reciprocal translocation
    »óÈ£(±³È¯)ÀüÁÂ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 12 ÆäÀÌÁö: 9
REC enlarged tip of a stem that bears the floral parts
REC the act of receiving
REC the act of catching a pass in football
REC quality or fidelity of a received broadcast
REC the manner in which something is greeted
REC a formal party of people
REC a counter (as in a hotel) where guests are received
REC a line of people (hosts and guests of honor) who welcome the guests at a reception party
REC a room for receiving and entertaining visitors (as in a private house or hotel)
REC a secretary whose main duty is to answer the telephone and receive visitors
REC of a nerve fiber or impulse originating outside and passing toward the central nervous system
REC open to arguments, ideas, or change
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 5 ÆäÀÌÁö: 9
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
ÅëÇÕ°Ë»ö ¿Ï·á